Factor VIII assay variability in postinfusion samples containing full length and B-domain deleted FVIII

Haemophilia

Volumn 22, Issue 5, 2016, Pages 806-812

  Kitchen, S ^a,b   Jennings, I ^a   Makris, M ^a,c   Kitchen, D P ^a   Woods, T A L ^a   Walker, I D ^a  

^a UK NEQAS Blood Coagulation   (United Kingdom)

^b Sheffield Haemophilia and Thrombosis Centre   (United Kingdom)

^c UNIVERSITY OF SHEFFIELD   (United Kingdom)

Author keywords

BDD FVIII; chromogenic FVIII assay; full length recombinant FVIII; monitoring FVIII; one stage FVIII assay

Indexed keywords

BLOOD CLOTTING FACTOR 8;

ARTICLE; ASSAY; CALIBRATION; CHROMOGENIC FACTOR VIII ASSAY; CONTROLLED STUDY; HEMOPHILIA A; HUMAN; PARTIAL THROMBOPLASTIN TIME; PLASMA; PRIORITY JOURNAL; PROTEIN DETERMINATION; PROTEIN DOMAIN;

EID: 84990190015     PISSN: 13518216     EISSN: 13652516     Source Type: Journal    
DOI: 10.1111/hae.12962     Document Type: Article

References (26)

1. Srivastava A, Brewer AK, Mauser-Bunschoten EP et al. G and Treatment Guidelines Working Group of the World Federation Of Hemophilia. Guidelines for Management of Haemophilia. Haemophilia 2013; 19: 1–47.
2. Keeling D, Tait C, Makris M. Guidelines on the selection and use of therapeutic products to treat haemophilia and other hereditary bleeding disorders. A Uk haemophilia centre doctors organisation guideline approved by the British Committee for Standards in Haematology. Haemophilia 2008; 14: 671–84.
3. Jennings I, Kitchen DP, Woods TAL, Kitchen S, Walker ID, Preston FE. Laboratory Performance in the World Federation of Hemophilia EQA programme, 2003-2008. Haemophilia 2009; 15: 571–7.
4. Preston FE, Kitchen S, Jennings I, Woods TAL, Makris M. SSC/ISTH classification of haemophilia A: can haemophilia centre laboratories achieve the new criteria? J Thromb Haemost 2004; 2: 271–4.
5. Lusher JM, Hillman-Wiseman C, Hurst D. In vivo recovery with products of very high purity – assay discrepancies. Haemophilia 1998; 4: 641–5.
6. Lee CA, Owens GB, Giangrande P et al. Pharmacokinetics of recombinant factor VIII (Recombinate) using one stage clotting and chromogenic factor VIII assay. Thromb Haemost 1999; 82: 1644–7.
7. Hubbard AR, Weller LJ, Bevan SA. A survey of one stage and chromogenic potencies in therapeutic factor VIII concentrates. Br J Haematol 2002; 117: 247–8.
8. Jennings I, Kitchen DP, Woods TAL, Kitchen S, Walker ID. Emerging technologies and quality assurance: the UK NEQAS perspective. Semin Thromb Haemost 2007; 33: 243–9.
9. Hubbard AR, Bevan SA, Weller LJ. Potency estimation of recombinant FVIII: effect of assay method and standard. Br J Haematol 2001; 113: 533–6.
10. Mikaelsson M, Oswaldson U, Sanderg H. Influence of phospholipids on the assessment of factor VIII activity. Haemophilia 1998; 4: 646–50.
11. Morfini M, Cinotti S, Bellatreccia A, Paladino E, Gingeri A, Mannucci PM. A multi-centre pharmacokinetic study of the B-domain deleted recombinant factor VIII concentrate suing different assays and standards. J Thromb Haemost 2003; 1: 2283–9.
12. Ingerslev J, Jankowski MA, Weston SB, Charles LA. Collaborative field study on the utility of a BDD factor VIII concentrate standard in the estimation of BDD Factor VIII: C activity in hemophilic plasma using the one-stage clotting assay. J Thromb Haemost 2004; 2: 623–8.
13. Santoro C, Iorio A, Ferrante F et al. Peformance of recalibrated ReFacto laboratory standard in the measurement of FVIIII plasma concentration via the chromogenic and one stage assays after infusion of recalibrated ReFacto (B domain deleted recombinant factor VIII). Haemophilia 2009; 15: 779–87.
14. Pouplard C, Caron C, Aillaud MF et al. The use of the new ReFacto AF laboratory standard allows reliable measurement of FVIII:C levels in ReFacto AF mock plasma samples by a one stage assay. Haemophilia 2011; 17: e958–62.
15. Cauchie M, Toelen J, Peerlinck K, Jacquemin M. Practical and cost-effective measurement of B-domain deleted and full-length recombinant FVIII in the routine haemostasis laboratory. Haemophilia 2013; 19: e133–8.
16. Mikaelsson M, Oswalksson U, Jankowski MA. Measurement of factor VIII activity of B-domain deleted recombinant factor VIII. Semin Haem 2001; 38: 13–23.
17. Viuff D, Barrowcliffe TW, Saugstrup T, Ezban M, Lillicrap D. International comparative field study of N8 evaluating factor VIII assay performance. Haemophilia 2011; 17: 695–702.
18. Hubbard AR, Dodt J, Lee T et al.; and on behalf of Factor VIII and Factor IX Subcommittee of The Science and Standardisation Committee of The International Society on Thrombosis and Haemostasis. Recommendations on the potency labelling of FVIII and FIX concentrates. J Thromb Haem 2013; 11: 988–9.
19. Jennings I, Kitchen DP, Woods TAL, Kitchen S, Preston FE, Walker ID. Stability of coagulation proteins in lyophilised plasma. Int J Lab Haematol 2015; 37: 495–502.
20. Kitchen S, Signer-Romero K, Key NS. Current laboratory practices in the diagnosis and management of haemophilia. Haemophilia 2015; 21: 550–7.
21. Gomez K, Chitlur M. Survey of laboratory tests used in the diagnosis and evaluation of haemophilia A. Thromb Haemost 2013; 109: 738–43.
22. Sommer JM, Moore N, Mcguffie-Valentine B et al. Comparative field study evaluating the activity of recombinant factor VIII Fc fusion protein in plasma samples at clinical haemostasis laboratories. Haemophilia 2014; 20: 294–300.
23. Kitchen S, Cartwright I, Woods TAL, Jennings I, Preston FE. Lipid composition of seven APTT reagents in relation to heparin sensitivity. Br J Haematol 1999; 106: 801–8.
24. Caron C, Dautzenberg MD, Delahousse B et al. A blinded in vitro study with ReFacto mock plasma samples: similar FVIII results between chromogenic assay and a one stage assay when using a higher cephalin dilution. Haemophilia 2002; 8: 639–43.
25. Mackie I, Cooper PC, Lawrie A, Kitchen S, Gray E, Laffan M; on behalf of British Committee for Standards in Haematology. Guidelines on the laboratory aspects of assays used in haemostasis and thrombosis. Int J Lab Haematol 2013; 35: 1–13.
26. Dodt J, Hubbard AR, Wicks SJ et al. Potency determination of factor VIII and factor IX for new product labelling and postinfusion testing: challenges for caregivers and regulators. Haemophilia 2015; 21: 543–9.